(Q66982502)

English

Dopamine receptor sensitivity in the hypothalamus of chronic schizophrenics after haloperidol therapy: Growth hormone and prolactin response to stimuli

scientific article published on 01 October 1979

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:523590%20AND%20SRC:MED&resulttype=core&format=json

1 September 2019

Dopamine receptor sensitivity in the hypothalamus of chronic schizophrenics after haloperidol therapy: growth hormone and prolactin response to stimuli (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:523590%20AND%20SRC:MED&resulttype=core&format=json

1 September 2019

Dopamine receptor sensitivity in the hypothalamus of chronic schizophrenics after haloperidol therapy: Growth hormone and prolactin response to stimuli (English)

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

author name string

F. Brambilla

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A523590

9 July 2022

L. Bellodi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A523590

9 July 2022

F. Negri

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A523590

9 July 2022

E. Smeraldi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A523590

9 July 2022

G. Malagoli

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A523590

9 July 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=523590

9 July 2022

publication date

1 October 1979

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:523590%20AND%20SRC:MED&resulttype=core&format=json

1 September 2019

full work available at URL

https://api.elsevier.com/content/article/PII:0306453079900167?httpAccept=text/xml

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

https://api.elsevier.com/content/article/PII:0306453079900167?httpAccept=text/plain

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Psychoneuroendocrinology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:523590%20AND%20SRC:MED&resulttype=core&format=json

1 September 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:523590%20AND%20SRC:MED&resulttype=core&format=json

1 September 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:523590%20AND%20SRC:MED&resulttype=core&format=json

1 September 2019

329-339

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:523590%20AND%20SRC:MED&resulttype=core&format=json

1 September 2019

Behavioral effects of l-Dopa in schizophrenic patients

1

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Dopamine and psychotic states: preliminary remarks

2

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Stimulation of Human-Growth-Hormone Secretion by L-Dopa

3

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Prolactin secretion in chronic schizophrenia

4

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

HLA system, psychiatry and psychopharmacology

6

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy

7

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Studies on prolactin in man

8

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Prolactin Responses to Neuroleptics in Normal and Schizophrenic Subjects

12

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms

14

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Enhanced prolactin inhibition following chronic treatment with haloperidol and morphine

16

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

The effect of L-dopa and chlorpromazine on prolactin and growth hormone secretion in normal women

17

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

The Dopamine Hypothesis of Schizophrenia A Critical Analysis

19

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Potentiation of levodopa stimulation of human growth hormone by systemic decarboxylase inhibition

20

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Neural regulation of growth hormone secretion

21

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

The Effect of Neuroleptics on Serum Prolactin in Schizophrenic Patients

23

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Nervous control of growth hormone secretion

25

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Postsynaptic supersensitivity in schizophrenia

26

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Dopamine receptor alteration in schizophrenia: neuroendocrine evidence

28

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Neuroendocrine studies with dopamine agonists in schizophrenia

29

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Neuroendocrine assessment of dopaminergic activity in schizophrenia

30

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

A Sensitive Double Antibody Immunoassay for Human Growth Hormone in Plasma

32

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

The HLA system and the clinical response to treatment with chlorpromazine

35

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs.

36

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

A neuroendocrine study of supersensitivity in tardive dyskinesia

37

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

The significance of dopamine for the mode of action of neuroleptics and the pathogenesis of schizophrenia

39

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients

40

1 reference

10.1016/0306-4530(79)90016-7

https://api.crossref.org/works/10.1016/0306-4530(79)90016-7

24 June 2023

Identifiers

10.1016/0306-4530(79)90016-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:523590%20AND%20SRC:MED&resulttype=core&format=json

1 September 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:523590%20AND%20SRC:MED&resulttype=core&format=json

1 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q66982502&oldid=1922973795"